Nippon Chemiphar Co., Ltd. 4539.T Stock
Nippon Chemiphar Co., Ltd. Price Chart
Nippon Chemiphar Co., Ltd. 4539.T Financial and Trading Overview
Nippon Chemiphar Co., Ltd. stock price | 1622 JPY |
Previous Close | 1818 JPY |
Open | 1810 JPY |
Bid | 1817 JPY x 0 |
Ask | 1825 JPY x 0 |
Day's Range | 1810 - 1825 JPY |
52 Week Range | 1634 - 2170 JPY |
Volume | 4K JPY |
Avg. Volume | 3.38K JPY |
Market Cap | 6.66B JPY |
Beta (5Y Monthly) | 0.331417 |
PE Ratio (TTM) | 15.234277 |
EPS (TTM) | -66.62 JPY |
Forward Dividend & Yield | 100 (5.46%) |
Ex-Dividend Date | March 28, 2024 |
1y Target Est | N/A |
4539.T Valuation Measures
Enterprise Value | 11.26B JPY |
Trailing P/E | 15.234277 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.21113469 |
Price/Book (mrq) | 0.35521066 |
Enterprise Value/Revenue | 0.357 |
Enterprise Value/EBITDA | 8.938 |
Trading Information
Nippon Chemiphar Co., Ltd. Stock Price History
Beta (5Y Monthly) | 0.331417 |
52-Week Change | -3.091% |
S&P500 52-Week Change | 20.43% |
52 Week High | 2170 JPY |
52 Week Low | 1634 JPY |
50-Day Moving Average | 1815.24 JPY |
200-Day Moving Average | 1761.86 JPY |
4539.T Share Statistics
Avg. Volume (3 month) | 3.38K JPY |
Avg. Daily Volume (10-Days) | 2.48K JPY |
Shares Outstanding | 3.65M |
Float | 2.19M |
Short Ratio | N/A |
% Held by Insiders | 35.84% |
% Held by Institutions | 10.67% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | 273.00% |
Payout Ratio | 0.4174 |
Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | March 31, 2023 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | March 31, 2024 |
Profitability
Profit Margin | 1.07% |
Operating Margin (ttm) | -0.76% |
Gross Margin | 25.93% |
EBITDA Margin | 3.99% |
Management Effectiveness
Return on Assets (ttm) | -0.30% |
Return on Equity (ttm) | 1.83% |
Income Statement
Revenue (ttm) | 31.56B JPY |
Revenue Per Share (ttm) | 8743.53 JPY |
Quarterly Revenue Growth (yoy) | -3.00000000000000000000000000000000% |
Gross Profit (ttm) | N/A |
EBITDA | 1.26B JPY |
Net Income Avi to Common (ttm) | 339M JPY |
Diluted EPS (ttm) | 119.73 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 10.53B JPY |
Total Cash Per Share (mrq) | 2917.29 JPY |
Total Debt (mrq) | 15.23B JPY |
Total Debt/Equity (mrq) | 82.18 JPY |
Current Ratio (mrq) | 2.264 |
Book Value Per Share (mrq) | 5134.981 |
Cash Flow Statement
Operating Cash Flow (ttm) | -916000000 JPY |
Levered Free Cash Flow (ttm) | -2646249984 JPY |
Profile of Nippon Chemiphar Co., Ltd.
Country | Japan |
State | N/A |
City | Tokyo |
Address | 2-2-3, Iwamoto-cho |
ZIP | 101-0032 |
Phone | 81 3 3863 1211 |
Website | https://www.chemiphar.co.jp |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Nippon Chemiphar Co., Ltd., together with its subsidiaries, engages in the manufacture, sale, import, and export of ethical pharmaceuticals and diagnostic agents in Japan and internationally. the company offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. It also develops NC-2400, a PPAR-delta agonist currently under phase 1 development; NC-2500, a novel advanced xanthine oxidoreductase inhibitor for the treatment of hyperuricemia/gout currently under phase 1 development; and NC-2600, a P2X4 receptor antagonist for the treatment of neuropathic pain currently under phase 1 development. In addition, the company develops NC-2700, a novel urate transporter 1 inhibitor that enhance excretion urate to urine currently under preclinical development; NC-2800, a delta opioid receptor agonist for the treatment of depression/anxiety currently under Phase 1 development; DFP-17720, a cancer microenvironment improving agent far pancreatic cancer currently under phase 2 development; and DE-P-14323, an anti-cancer agent for non-small cell lung cancer currently under phase 2 development. Further, it is involved in the development of Soleton, an analgesic and anti-inflammatory drug; and Calvan, a blocker for huntington's disease currently under phase 2 development. Additionally, the company provides quasi-drugs, nutrients, health foods, cosmetics, and various type of creams. It distributes its generic pharmaceuticals through wholesalers to hospitals and pharmacies. The company was formerly known as Hitachi Chemical Co., Ltd. and changed its name to Nippon Chemiphar Co., Ltd. in 1970. Nippon Chemiphar Co., Ltd. was incorporated in 1950 and is headquartered in Tokyo, Japan.
Q&A For Nippon Chemiphar Co., Ltd. Stock
What is a current 4539.T stock price?
Nippon Chemiphar Co., Ltd. 4539.T stock price today per share is 1622 JPY.
How to purchase Nippon Chemiphar Co., Ltd. stock?
You can buy 4539.T shares on the Tokyo exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Nippon Chemiphar Co., Ltd.?
The stock symbol or ticker of Nippon Chemiphar Co., Ltd. is 4539.T.
Which industry does the Nippon Chemiphar Co., Ltd. company belong to?
The Nippon Chemiphar Co., Ltd. industry is Drug Manufacturers-Specialty & Generic.
How many shares does Nippon Chemiphar Co., Ltd. have in circulation?
The max supply of Nippon Chemiphar Co., Ltd. shares is 3.65M.
What is Nippon Chemiphar Co., Ltd. Price to Earnings Ratio (PE Ratio)?
Nippon Chemiphar Co., Ltd. PE Ratio is now.
What was Nippon Chemiphar Co., Ltd. earnings per share over the trailing 12 months (TTM)?
Nippon Chemiphar Co., Ltd. EPS is -66.62 JPY over the trailing 12 months.
Which sector does the Nippon Chemiphar Co., Ltd. company belong to?
The Nippon Chemiphar Co., Ltd. sector is Healthcare.